[en] [en] OBJECTIVES: In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them.
METHODS: For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton-Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types.
RESULTS: Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak.
CONCLUSIONS: These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.
Disciplines :
Immunology & infectious disease
Author, co-author :
Deplano, Ariane ; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
Hallin, Marie ; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium ; Centre for Environmental Health and Occupational Health, Public Health School, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
Bustos Sierra, Natalia ; Scientific Directorate of Epidemiology and Public Health, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium
Michel, Charlotte ; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
Prevost, Benoit; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
MARTINY, Delphine ; Université de Mons - UMONS > Faculté de Médecine et de Pharmac > Service du Doyen de la Faculté de Médecine et Pharmacie ; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
Yin, Nicolas ; Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium
Language :
English
Title :
Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.
O'Neill AJ, Larsen AR, Skov R et al. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 2007; 45: 1505-10. https://doi.org/10.1128/JCM.01984-06
Laurent F, Tristan A, Croze M et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J Antimicrob Chemother 2008; 63: 420-1. https://doi.org/10.1093/jac/dkn456
Rijnders MIA, Wolffs PFG, Hopstaken RM et al. Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands. J Antimicrob Chemother 2012; 67: 1176-80. https://doi.org/10.1093/jac/dkr590
Rørtveit S, Skutlaberg DH, Langeland N et al. The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in western Norway. Scand J Infect Dis 2014; 46: 832-7. https://doi.org/10.3109/00365548.2014.947317
BAPCOC. Guide belge de traitement anti-infectieux en pratique ambulatoire/Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. 2022. https://organesdeconcertation.sante.belgique.be/fr/documents/guide-belge-de-traitement-anti-infectieux-en-pratique-ambulatoire-2022.
Bons SCS, Bouma M, Draijer LW et al. Bacteriële huidinfecties (M68). 2019. https://richtlijnen.nhg.org/files/pdf/61-Bacteri%C3%ABle%20huidinfecties-mei-2019.pdf.
Maes N, Magdalena J, Rottiers S et al. Evaluation of a Triplex PCR assay to discriminate Staphylococcus aureus from coagulase-negative staphylococci and determine methicillin resistance from blood cultures. J Clin Microbiol 2002; 40: 1514-7. https://doi.org/10.1128/JCM.40.4.1514-1517.2002
Ramsey MA, Bradley SF, Kauffman CA et al. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother 1996; 40: 2820-3. https://doi.org/10.1128/AAC.40.12.2820
Jarraud S, Mougel C, Thioulouse J et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 2002; 70: 631-41. https://doi.org/10.1128/IAI.70.2.631-641.2002
Hallin M, Friedrich AW, Struelens MJ. Spa typing for epidemiological surveillance of Staphylococcus aureus. Methods Mol Biol 2009; 551: 189-202. https://doi.org/10.1007/978-1-60327-999-4-15
Harmsen D, Claus H, Witte W et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003; 41: 5442-8. https://doi.org/10.1128/JCM.41.12.5442-5448.2003
Hallin M, Deplano A, Denis O et al. Validation of pulsed-field gel electrophoresis and spa typing for long-term, nationwide epidemiological surveillance studies of Staphylococcus aureus infections. J Clin Microbiol 2007; 45: 127-33. https://doi.org/10.1128/JCM.01866-06
Koning S, Sande R, Verhagen A et al. Interventions for impetigo. Cochrane Database Syst Rev 2012; issue 1: CD003261.
Haute autorité de santé. Prise en charge des infections cutanées bactériennes courantes. 2019. https://www.has-sante.fr/upload/docs/application/pdf/2019-04/prise-en-charge-des-infections-cutanees-bacteriennes-courantes-recommandations.pdf.
National Institute for Health and Care Excellence. Impetigo: antimicrobial prescribing. 2020. https://www.nice.org.uk/guidance/ng153.
Loffeld A, Davies P, Lewis A et al. Seasonal occurrence of impetigo: a retrospective 8-year review (1996-2003). Clin Exp Dermatol 2005; 30: 512-4. https://doi.org/10.1111/j.1365-2230.2005.01847.x
Vendrik KEW, Kuijper EJ, Dimmendaal M et al. An unusual outbreak in The Netherlands: community-onset impetigo caused by a meticillin-resistant Staphylococcus aureus with additional resistance to fusidic acid, June 2018 to January 2020. Euro Surveill 2022; 27: 2200245. https://doi.org/10.2807/1560-7917.ES.2022.27.49.2200245
Yang LPH, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008; 68: 855-73. https://doi.org/10.2165/00003495-200868060-00008
Gorges H, Hall L, Heal C. Feasibility study for a randomised controlled trial for the topical treatment of impetigo in Australian general practice. Trop Med Infect Dis 2021; 6: 197.
